

## The association of Factor XIII 100 G/T polymorphism and the risk of deep venous thromboembolism: An in silico and experimental study

Nasrin Bargahi<sup>1</sup>, Ahmad Poursadegh Zonouzi<sup>1</sup>, Hedy Fardmanesh<sup>2</sup>, Saeid Ghorbian<sup>3</sup>, Ali Akbar Poursadegh Zonouzi<sup>2</sup>

<sup>1</sup>Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup>Department of Genetics and Medical Biotechnology, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

<sup>3</sup>Department of Molecular Biology, Ahar Branch, Islamic Azad University, Ahar, Iran

Accepted 28 February 2016; Spring-Summer2016

### ABSTRACT

**Introduction:** Several lines of evidence suggest that the Factor XIII (FXIII) 100 G/T polymorphism may influence susceptibility to deep venous thromboembolism (DVT). To explore this hypothesis, we investigated whether this polymorphism is associated with the predisposition to DVT. We also predict the possible impact of residue substitution at codons 34 (Val34Leu) in A subunits of the FXIII coagulation factor on the structure and function of it.

**Methods:** A total of 693 individuals were included in the current study, 193 patients with DVT clinical symptoms, and 500 healthy subjects without both personal and family histories of thromboembolic disorders. Genotyping was carried out using the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique. To predict the potentially effects of residue changes at codons 34 on the structure and function of the FXIII, we used Polymorphism Phenotyping (PolyPhen) online software.

**Results:** No significant difference in the genotypes distribution of the FXIII 100 G/T gene polymorphism was detected between DVT patients and healthy controls ( $P > 0.05$ ). Our results showed that the frequency of the mutated FXIII 100T allele was not statistically significant different between two group. Using PolyPhen online software, residue substitution at codons 34 of the FXIII was predicted to be benign.

**Conclusion:** Our in silico and experimental findings indicated that the FXIII 100 G/T gene polymorphism is not associated with DVT.

**Key words:** Deep Venous Thromboembolism, FXIII 100 G/T Polymorphism, Thrombophilia, PolyPhen

\*Corresponding author: Tel: +989148149131

E-mail address: ali.poursadegh@yahoo.com (Ali Akbar Poursadegh Zonouzi)





**Table 2. The genotype distribution of the FXIII 100 G/T polymorphism in case and control groups**

	Case group (n=193) %	Control group (n=500) %	P value <sup>a</sup>
<b>FXIII 100 G/T <sup>b</sup></b>			0.517
<b>GG</b>	72.02	74.60	
<b>GT</b>	24.87	23.60	
<b>TT</b>	3.11	1.80	

Abbreviations: F XIII; Factor XIII.

<sup>a</sup> P value calculated by chi-square test<sup>b</sup> FXIII, at nucleotide position 100 on the gene a G was exchanged by a T**Table 3. The heterozygote and homozygote genotypes and mutant allele frequencies of the FXIII 100 G/T polymorphism in case and control groups**

	Case group (n=193) %	Control group (n=500) %	P value <sup>a</sup>	OR	95 % CI
<b>FXIII 100 G/T <sup>b</sup></b>					
GT	24.87	23.60	0.766	0.933	0.634 - 1.373
TT	3.11	1.80	0.381	0.571	0.201 - 1.627
Frequency of T allele	15.54	13.60	0.346	0.855	0.615 - 1.189
Carrier (GT+ TT) <sup>c</sup>	27.98	25.40	0.500	0.876	0.603 - 1.273

Abbreviations: F XIII; Factor XIII, OR; Odds Ratio, CI; Confidence Interval

<sup>a</sup> P value calculated by chi-square test<sup>b</sup> FXIII, at nucleotide position 100 on the gene a G was exchanged by a T<sup>c</sup> Carriers: individuals who had either heterozygous or homozygous specified mutation

The frequencies of mutated FXIII 100T allele in case and control subjects was also calculated (see Table 3). We found that the prevalence of mutated FXIII 100T allele was more frequent in the case subjects but, did not show a statistically significant difference ( $P>0.05$ ) (see Table 3).

Finally, we unified the heterozygote and homozygote genotypes of each group into a new group (carrier group) and then the odds ratios (OR) and 95% confidence intervals (CI) were calculated. Our data showed that the FXIII 100 G/T polymorphism is not associated with the increased risk of DVT (see Table 3).

#### **Prediction of Functional Effect of Factor XIII Val34Leu polymorphism**

The substitution of valine by leucine at codon 34 was predicted to be benign by PolyPhen online software (see Figure 1).



**Figure 1. In silico analysis of the Factor XIII 100 G/T polymorphism using PolyPhen. The substitution of leucine a valine for a valine at codon 34 in FXIII coagulation factor was predicted to be benign.**

### Conclusion:

As indicated earlier, increasing evidences suggest that the procoagulant, anticoagulant and fibrinolytic systems deficiencies play a fundamental role in susceptibility to thromboembolic disorders [6]. To our knowledge, here, the possible association between FXIII 100 G/T polymorphism with DVT in Northwestern Iran was investigated in the current study for the first time. Our results revealed that the prevalence of the FXIII 100 G/T polymorphism was not statically significant different between case and control subjects in our population ( $P>0.05$ ).

However, a high prevalence of this polymorphism in the patient group was detected. We also found that the frequency of mutated FXIII 100T allele was higher in the DVT patients than in healthy controls, but this difference was not statistically significant ( $P>0.05$ ). Therefore, it seems that the presence of the FXIII 100T allele is not associated with DVT, based upon our experimental results. Our results are in accordance with the findings of several previous studies that have been published in this field. Corral *et al*, reported that Factor XIII 100T allele does not has any effect on the risk of venous thrombosis in the Spanish population [10]. Le Gal *et al*, studied 286 patients with idiopathic VTE and 286 healthy controls for FXIII 100 G/T polymorphism and reported that FXIII 100T allele was significantly associated with a lower risk of VTE [11]. Similar data were obtained in a

study by Renner *et al*, who investigated FXIII 100 G/T polymorphism in 154 DVT patients and 308 healthy controls in Austrian population and reported that presence of the FXIII 100T allele is associated with a decreased risk for DVT [13]. Moreover, Van Hylckama Vlieg *et al*, demonstrated that FXIII 100T allele was associated with a slightly decreased thrombotic risk [14]. In light of these studies and meta-analysis studies by Wells *et al*, and Gohil *et al*, provided additional evidence to support the hypothesis that the FXIII 100 G/T polymorphism has a significant protective effect against VTE [15, 16]. It has been proposed that the Leu34 FXIII is activated by thrombin more rapidly than their Val34 variant [17]. Although, the presence of FXIII Leu34 allele increases the catalytic activity of FXIII but it decreases clot stability and resistance to fibrinolysis through alteration of clot structure [16]. A study by Ariens *et al*, suggested that fibrin clots formed in the presence of Leu34 FXIII allele have finer structures with thinner fibers, smaller pores, and altered permeation characteristics when compared with fibrin clots formed in the presence of the Val34 variant [17, 18]. The findings of these studies have suggested that thinner and less porous fibrin clots relatively resistant to plasmin degradation [17,18]. Hence, it is conceivable that the FXIII 100 G/T polymorphism is associated with pathogenesis of VTE. Therefore, the role of FXIII 100 G/T polymorphism in pathogenesis of DVT remained controversial.

In conclusion, our in silico and experimental results revealed that the FXIII 100 G/T polymorphism is not associated with DVT. However, in spite of the negative association reported in the current study, the possible role of FXIII 100 G/T polymorphism in DVT pathogenesis could not be completely ruled out, and further studies will be needed to conclusively find association between this polymorphism and DVT.

### Acknowledgment:

The authors would like to express our sincerest appreciation to all the subjects for participating in this study.

**Declaration of conflicting interests**

There are no potential conflicts of interest for each author, concerning the submitted manuscript.

**References:**

1. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. *Hematol Am Soc Hematol Educ Program*. 2004; 1: 439-456.
2. Farajzadeh M, Bargahi N, Poursadegh Zonouzi A, Farajzadeh D, Pouladi N. Polymorphisms in thrombophilic genes are associated with deep venous thromboembolism in an Iranian population. *Meta Gene*. 2014; 2: 505-513.
3. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. *Hum Genet*. 2001; 109: 369-384.
4. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. *Arterioscler Thromb Vasc Biol*. 2011; 31: 485-493.
5. Rahimi Z, Mozafari H, Shahriari-Ahmadi A, Alimogaddam K, Ghavamzadeh A, Aznab M, Mansouri K, Rezaei M, Parsian A. Deep venous thrombosis and thrombophilic mutations in western Iran: association with factor V Leiden. *Blood Coagul Fibrinolysis*. 2010; 21: 385-388.
6. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus*. 2011; 2:120-138.
7. Cushman M, Cornell A, Folsom AR, Wang L, Tsai MY, Polak J, Tang Z. Associations of the beta-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis. *Thromb Res*. 2007; 121:339-345.
8. Balogh I, Szoke G, Karpatai L, Wartiovaara U, Katona E, Komaromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. *Blood*. 2000; 96: 2479-286.
9. Hsieh L, Nugent D. Factor XIII deficiency. *Haemophilia*. 2008; 14: 1190-1200.
10. Corral J, Gonzalez-Conejero R, Iniesta JA, Rivera J, Martinez C, Vicente V.

The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. *Haematologica*. 2000; 85: 293-297.

11. Le Gal G, Delahousse B, Lacut K, Malaviole V, Regina S, Blouch MT, Couturaud F, Mottier D, Oger E, Gruel Y; Groupe d'Etudes sur la Thrombose des Hôpitaux Universitaires du Grand Ouest. Fibrinogen Aalpha-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism. *Thromb Res*. 2007; 121: 333-338.
12. Hoppe B, Heymann GA, Koscielny J, Hellstern P, Kiesewetter H, Salama A. Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system. *Thromb Res*. 2003; 111:115-120.
13. Renner W, Koppel H, Hoffmann C, Schallmoser K, Stanger O, Toplak H, Wascher TC, Pilger E. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. *Thromb Res*. 2000; 99:35-39.
14. Van Hylckama Vlieg A, Komanasin N, Ariëns RA, Poort SR, Grant PJ, Bertina RM, Rosendaal FR. Factor XIII Val34Leu polymorphism, factor XI II antigen levels and activity and the risk of deep venous thrombosis. *Br J Haematol*. 2002; 119: 169-175.
15. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. *Am J Epidemiol*. 2006;164: 101-109.
16. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. *Thromb Haemost*. 2009; 102: 360-370.
17. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. *Blood*. 2002; 100: 743-754.
18. Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. *Blood*. 2000; 96: 988-995